前列腺癌VEGFR-3和CD31表达与肿瘤转移的研究  

Study on the Expression of VEGFR-3,CD 31 and Their Correlation with Metastasis of Prostate Cancer

作　　者：徐银峰[1] 丁国芳[1] 孙瑜[1] 李继承[2] 

机构地区：[1]浙江海洋学院医学院,舟山316004 [2]浙江大学细胞生物学研究所

出　　处：《浙江中医学院学报》2005年第5期14-17,共4页Journal of Zhejiang College of Traditional Chinese Medicine

基　　金：浙江省教育厅科研基金资助项目(20040540)

摘　　要：目的:研究前列腺癌组织VEGFR-3(flt4)和CD31的表达与前列腺癌中的新生血管、淋巴管的生成及肿瘤转移的关系。方法:用EnVisionTM免疫组织化学及图像分析法,检测前列腺癌组织VEGFR-3和CD31表达;用Weidner最高血管密度计数法,计数阳性淋巴管数(MLC)和微血管密度(MVD)。结果:前列腺癌组织MLC(8·26±2·13/mm2)和MVD(75·06±14·38/mm2)显著高于癌周组织的MLC(4·75±1·19/mm2)和MVD(31·33±15·47/mm2),两者比较具有显著性差异(P<0·01)。VEGFR-3和CD31的表达之间存在正相关(P<0·05,r=0·6418)。有淋巴转移和TNM分期Ⅲ、Ⅳ期的前列腺癌患者MLC、MVD分别高于无淋巴转移和Ⅰ、Ⅱ期患者,均具有显著性差异(P<0·01,P<0·05)。前列腺癌在不同的组织学分级的差异,无统计学意义(P>0·05)。结论:前列腺癌组织中的VEGFR-3和CD31表达水平与肿瘤的转移密切相关;前列腺癌组织MLC和MVD的显著增高,提示肿瘤组织有淋巴管和血管的生成,可作为判断肿瘤转移的生物学指标。Objective：To investigate the relationship between the expression of vascular endothelial growth factor receptor-3（VEGFR-3）and CD 31 and to expound the metastasis mechanism of prostate cancer. Methods： VEGFR-3 and CD 31 expression were examined by immunohistochemical methods of Envision,VEGFR-3 positive microlymphatic count（MLC）and microvessel density（ MVD） were appraised by the Weidner highest microvessel density and imageanalysis. Results： Both MLC and MVD in prostate cancer were higher than MLC,MVD in normal tissues（P〈0.01）. There was significant correlation between the expression of VEGFR. 3 and CD 31 （P〈0.05,r=0. 6418）. In prostate cancer,MLC and MVD were higher in the cases of clinical stage Ⅲ～Ⅳ and with lymphatic metastasis than those of clinical stage Ⅰ～Ⅱ and without lymphatic metastasis respectively（P〈0.05）, There were no significant differences between MLC, MVD and histologic type,histologie grade（differentiation）in prostate cancer（P〉0.05）. Conclutions： VEGFR-3 and CD 31 expression correlated significantly with metastasis, MLC and MVD might predict peritumoral lymphangiogenesis,angiogenesis,which may be as a biologic marker of metastasis in prostate cancer.

关 键 词：前列腺癌 VEGFR-3 CD31 肿瘤转移 前列腺癌组织 CD31表达 微血管密度(MVD) 前列腺癌患者 显著性差异 免疫组织化学 

分 类 号：R979.1[医药卫生—药品] R737.25[医药卫生—药学]